Ge Healthcare Technologies (GEHC) Stock
Global provider of diagnostic imaging and patient monitoring tools. Here's the price, business snapshot, and what's worth knowing about Ge Healthcare Technologies in November 2026.
GE HealthCare Technologies Inc. (GEHC) is a global medical technology and services company focused on diagnostic imaging, ultrasound, patient monitoring, life‑sciences tools and bioprocessing, and healthcare IT. With a market capitalisation around $34.7 billion, the business combines capital equipment sales with recurring revenue from service contracts, consumables and software – a mix that can smooth cyclicality in equipment purchases. Key growth drivers include demand for imaging and diagnostics, expansion of bioprocessing for biologics, and adoption of digital and AI tools to improve workflows. Investors should be aware of sensitivity to hospital and clinic capital spending cycles, competitive pressures, reimbursement and regulatory risk, and supply‑chain dynamics. Management execution and capital allocation also matter for returns. This summary is educational only, not personalised advice: values can rise and fall and past performance is not a guide to the future. Check up‑to‑date filings and consult a financial adviser when assessing suitability for your portfolio.
Why It’s Moving
GE HealthCare Balances AI Product Momentum Against Tariff and Margin Headwinds
- The launch of Allia Celeo expands the interventional imaging portfolio with AI-powered precision and flexible workflows, signaling continued investment in high-throughput procedural solutions.
- New AI-assisted capabilities for Vscan Air, including Lung Guidance and AutoAS, reinforce GEHC's leadership in point-of-care diagnostics for cardiac and respiratory assessments.
- Despite raising the 2026 earnings outlook on strong Q3 performance, management highlighted persistent tariff risks and margin pressures that could impact fourth-quarter growth.
GE HealthCare Balances AI Product Momentum Against Tariff and Margin Headwinds
- The launch of Allia Celeo expands the interventional imaging portfolio with AI-powered precision and flexible workflows, signaling continued investment in high-throughput procedural solutions.
- New AI-assisted capabilities for Vscan Air, including Lung Guidance and AutoAS, reinforce GEHC's leadership in point-of-care diagnostics for cardiac and respiratory assessments.
- Despite raising the 2026 earnings outlook on strong Q3 performance, management highlighted persistent tariff risks and margin pressures that could impact fourth-quarter growth.
Sixth Month Growth Performance
When is the next earnings date for GE HEALTHCARE TECHNOLOGIES INC (GEHC)?
No confirmed upcoming earnings date has been announced for GEHC as of November 2, 2026. Based on the company's historical reporting pattern, which typically occurs approximately three months after the previous quarter's close, the next report is expected in February 2027. This upcoming release will cover the fourth quarter and full-year results for fiscal year 2026.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying GE Healthcare's stock, anticipating it will rise to $90.31.
Financial Health
GE Healthcare is performing well with strong revenue, cash flow, and profitability indicators.
Dividend
GE Healthcare's dividend yield of 0.18% is low, making it less attractive for dividend-seeking investors. If you invested $1000 you would be paid $1.80 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Diagnostics and Imaging
Imaging equipment drives sales and higher‑margin service revenue; technological upgrades and AI could support demand, though hospital budgets and reimbursement affect timing.
Life Sciences Growth
Bioprocessing and tools for biologics offer expansion opportunities as biologics production rises, but competition and capital intensity can affect margins.
Global Service Network
Recurring revenue from service contracts and consumables provides stability and customer ties, yet geographic exposure and supply chains can influence performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
